Merck KGaA Highlights First In Class Five For 2025 Market Boom
From BTK inhibitors in multiple sclerosis to candidates aiding cancer cell death, Merck KGaA is focusing on its first-in-class pipeline which it expects to make a significant impact from 2025.
You may also be interested in...
Pfizer and BioNTech’s Comirnaty supply under existing agreements will continue as planned despite anticipated expansion into a new child sub-population in Europe.
Increases in liver enzymes and fat could dampen approval prospects despite vupanorsen meeting its mid-stage primary endpoint, some analysts have said.
Emerging Company Profile: Cybin’s novel approach to psilocybin therapeutics aims for better safety, shorter duration and less variability through the process of deuteration.